194 related articles for article (PubMed ID: 21701902)
1. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.
Piratvisuth T; Marcellin P; Popescu M; Kapprell HP; Rothe V; Lu ZM
Hepatol Int; 2013 Jun; 7(2):429-36. PubMed ID: 21701902
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
3. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
4. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.
Sun J; Hou JL; Xie Q; Li XH; Zhang JM; Wang YM; Wang H; Lai JY; Chen SJ; Jia JD; Sheng JF; Chan HL; Wang JF; Li MK; Jiang M; Popescu M; Sung JJ
Aliment Pharmacol Ther; 2011 Aug; 34(4):424-31. PubMed ID: 21692822
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.
Marcellin P; Bonino F; Yurdaydin C; Hadziyannis S; Moucari R; Kapprell HP; Rothe V; Popescu M; Brunetto MR
Hepatol Int; 2013 Mar; 7(1):88-97. PubMed ID: 23518903
[TBL] [Abstract][Full Text] [Related]
7. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.
Chan HLY; Chan FWS; Hui AJ; Li MKK; Chan KH; Wong GLH; Loo CK; Chim AML; Tse CH; Wong VWS
J Viral Hepat; 2019 Jan; 26(1):126-135. PubMed ID: 30187604
[TBL] [Abstract][Full Text] [Related]
8. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
10. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B.
van Bömmel F; van Bömmel A; Krauel A; Wat C; Pavlovic V; Yang L; Deichsel D; Berg T; Böhm S
J Infect Dis; 2018 Aug; 218(7):1066-1074. PubMed ID: 29741634
[TBL] [Abstract][Full Text] [Related]
11. Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
Marcellin P; Xie Q; Woon Paik S; Flisiak R; Piratvisuth T; Petersen J; Asselah T; Cornberg M; Ouzan D; Foster GR; Papatheodoridis G; Messinger D; Regep L; Bakalos G; Alshuth U; Lampertico P; Wedemeyer H
PLoS One; 2020; 15(4):e0230893. PubMed ID: 32275726
[TBL] [Abstract][Full Text] [Related]
12. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Wong VW; Wong GL; Yan KK; Chim AM; Chan HY; Tse CH; Choi PC; Chan AW; Sung JJ; Chan HL
Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
[TBL] [Abstract][Full Text] [Related]
13. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.
Jia W; Zhu MQ; Qi X; Wang T; Wen X; Chen PD; Fan QQ; Zhang WH; Zhang JM
Virol J; 2019 May; 16(1):61. PubMed ID: 31064399
[TBL] [Abstract][Full Text] [Related]
14. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
15. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
Piratvisuth T; Lau G; Chao YC; Jin R; Chutaputti A; Zhang QB; Tanwandee T; Button P; Popescu M
Hepatol Int; 2008 Mar; 2(1):102-10. PubMed ID: 19669285
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.
Rinker F; Bremer CM; Schröder K; Wiegand SB; Bremer B; Manns MP; Kraft AR; Wedemeyer H; Yang L; Pavlovic V; Wat C; Gerlich WH; Glebe D; Cornberg M
Liver Int; 2020 Feb; 40(2):324-332. PubMed ID: 31721419
[TBL] [Abstract][Full Text] [Related]
17. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.
Marcellin P; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Jin R; Gurel S; Lu ZM; Wu J; Popescu M; Hadziyannis S;
Gastroenterology; 2009 Jun; 136(7):2169-2179.e1-4. PubMed ID: 19303414
[TBL] [Abstract][Full Text] [Related]
18. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
19. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.
Goulis I; Karatapanis S; Akriviadis E; Deutsch M; Dalekos GN; Raptopoulou-Gigi M; Mimidis K; Germanidis G; Drakoulis C; Triantos C; Zintzaras E; Bakalos G; Papatheodoridis G
Liver Int; 2015 May; 35(5):1540-8. PubMed ID: 25368957
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.
Charatcharoenwitthaya P; Sukeepaisarnjaroen W; Piratvisuth T; Thongsawat S; Sanpajit T; Chonprasertsuk S; Jeamsripong W; Sripariwuth E; Komolmit P; Patcharatrakul T; Boonsirichan R; Bunchorntavakul C; Tuntipanichteerakul S; Tanwandee T;
J Gastroenterol Hepatol; 2016 Nov; 31(11):1874-1881. PubMed ID: 26997582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]